Glenmark Launches Ryaltris in Brazil for Rhinitis

has expanded its global respiratory innovation footprint with the launch of Ryaltris in Brazil. The introduction marks the entry of the company’s differentiated dual-action therapy for allergic rhinitis into the Brazilian market. Ryaltris combines an antihistamine and a corticosteroid in a single nasal spray, offering convenient symptom relief for patients. The launch strengthens Glenmark’s presence in emerging markets and builds on the product’s existing approvals across multiple countries. This move supports the company’s strategy to grow its innovative respiratory portfolio and enhance access to advanced treatments for allergic rhinitis in Latin America. The Brazil launch is expected to contribute to Glenmark’s international specialty business expansion. **Top stocks in the pharmaceuticals industry:** Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla.